August 16, 2010

R-Tech Ueno Submits a Request for Arbitration against Takeda Pharmaceutical

August 12, 2010

Please see "Quarterly report for the 1st quarter of fiscal year ending March 31, 2011 (Japanese Version)" which is shown on our Japanese website.

August 12, 2010

Please see "Announcement of business result for the 1st quarter of fiscal year ending March 31, 2011 (Japanese Version)" which is shown on our Japanese website.

July 22, 2010

Announcement of Change in Storage Condition for Rescula® Eye Drops 0.12%

July 15, 2010

Notification related to the Completion of the Phase II Clinical Study of the Ophthalmic Solution UF-021 (product name Ocuseva(TM)) on Retinitis Pigmentosa (2)

July 2, 2010

Announcement of Termination of Licensing Agreement for Rescula® Eye Drops

June 28, 2010

Please see "Annual securities report for the fiscal year ending March 31, 2010 (Japanese Version)" which is shown on our Japanese website.

June 10, 2010

Lubiprostone Successfully Completes Phase 3 Efficacy Trial in Japanese Patients

June 3, 2010

Notification related to the Completion of the Phase II Clinical Study of UF-021 (product name Ocuseva(TM)) on Retinitis Pigmentosa

May 13, 2010

Announcement of License Agreement for Rescula® Eye Drops with Novartis Pharma

May 13, 2010

Please see "Announcement of business result for the fiscal year ending March 31, 2010 (Japanese Version)" which is shown on our Japanese website.

May 6, 2010

R-Tech Ueno's Sanda Factory Passes Inspection for the Manufacture of Rescula® Eye Drops

April 28, 2010

R-Tech Ueno Starts Contract Manufacturing of Liquid-filled Capsules

April 5, 2010

Notification Regarding the Application for Marketing Approval of Latanoprost Eye Drops 0.005% in Japan